GLP-1 reshapes Asian consumer stocks as impulse spending drops 84%

Weight-loss drugs are dismantling Asia's impulse-consumption model, with 84% of 533 GLP-1 users surveyed by J.P. Morgan reporting a lower urge to splurge.

"The impact extends beyond high-calorie food to an entire consumption chain built on desire, convenience, habit, occasion permission and repeat purchases," J.P. Morgan's Asia consumer research team said in an Aug. 9 report.

The survey of current GLP-1 users across China (175), India (183) and South Korea (175) found 79% cut snacks, 77% reduced fried foods, 70% trimmed sugary drinks, 62% drank less alcohol and 74% ordered fewer food deliveries. Meanwhile, 62% increased gym spending, 58% bought more protein supplements and 51% spent more on medical checkups.

The implications for Asian consumer stocks extend beyond food and beverage. J.P. Morgan identified three risk layers — ticket size, purchase frequency and consumption occasion — and warned valuations may reprice before earnings show any impact. Key triggers include oral GLP-1 approvals in China, with Eli Lilly's orforglipron potentially approved as early as late 2026, and domestic semaglutide launches from 2027.

The survey reveals a pattern that cuts across vastly different food cultures. Chinese users cut milk tea, Indian users reduced instant noodles, pizza and traditional sweets, and Korean users trimmed fried chicken, side dishes and baked goods. Local products differ, but the behavioral direction is consistent.

More striking is that restraint extends to categories with no direct caloric link. Nearly 70% of tobacco users in the sample reduced consumption, and 92% said social dining was affected while 89% reported more restrained holiday spending. J.P. Morgan attributes this to a broader "desire effect" rather than simple dietary adjustment.

Convenience no longer guarantees conversion

The risk to food delivery and fast food goes beyond smaller order sizes. In the sample, 79% said fast food spending or frequency declined, 74% reduced delivery orders, and 68% increased home cooking. In China — where delivery infrastructure is among the world's most developed — 74% still cut delivery orders and 80% increased home cooking.

J.P. Morgan frames this as a three-layer risk: ticket size risk (still buying but less), frequency risk (buying less often), and occasion risk (the consumption occasion itself disappears). Frequency risk is harder to hedge than ticket size, and occasion risk is harder still.

Where the money goes: fitness, protein and medical aesthetics

GLP-1 users are not closing their wallets — they are redirecting spending. Beyond fitness and protein, 44% increased sportswear spending, 40% increased skincare, and 31% increased medical aesthetics. Travel spending rose for 26%, gold and jewelry for 18%, and personal electronics, luxury accessories and perfume each rose about 17%.

J.P. Morgan summarizes this as "control is the new convenience." Old convenience made desire easier to convert into consumption; new convenience makes progress easier to sustain. The bank divides affected companies into three groups: those dependent on automatic consumption (negative impact), those transitioning into nutrition and functional foods (mixed), and those serving goal-driven demand (positive).

GLP-1 penetration in Asia remains low, and the survey measures current-user behavior rather than forecasting adoption. But consumer stock multiples capitalize future frequency, repeat purchases, store efficiency and customer lifetime value. Once investors begin questioning those assumptions, earnings can lag while valuations move first.

Three signals from the survey could accelerate that repricing: 89% of users plan to continue GLP-1 for at least six to 12 more months, 71% have recommended the drugs to others, and 79% expect some new habits to persist after stopping. Gallup data shows U.S. adult GLP-1 usage rose from about 3% in 2024 to 11% in 2026, with cumulative usage at 15%.

J.P. Morgan flagged three timeline triggers: oral GLP-1 entry into Asia — Novo Nordisk's oral Wegovy was approved in the U.S. in December 2025 and Eli Lilly's orforglipron in April 2026, with the latter potentially approved in China as early as late 2026 to early 2027; China's first domestic semaglutide approvals expected from 2027, with more than 10 local companies potentially driving price competition; and consumer companies launching GLP-1-specific products such as muscle-preserving protein and portion-controlled packaging.

The ultimate question is not whether GLP-1 will push all consumer stocks down. It is which companies earned their growth from consumer impulse versus consumer goals. The former must prove they are not solely dependent on frequency and occasion; the latter must prove goal-driven spending can repeat. Valuation divergence may begin there.

This article is for informational purposes only and does not constitute investment advice.